Physician profile
Rahim Wooley
NPI 1952643157
$5,088.26
in general payments reported to CMS, 2019-2025
33 companies · $1,405 in 2025
The $1,405 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154 · 2020: $376 · 2021: $463 · 2022: $1,259 · 2023: $653 · 2024: $780 · 2025: $1,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,759 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,758.52 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,345.85 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $672.13 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.35 | 2020-2025 | Ofev, Jascayd, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $415.73 | 2020-2025 | Glassia, Cuvitru |
| Insmed, INC. | $194.03 | 2024-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $166.31 | 2020-2025 | |
| La Jolla Pharmaceutical Company | $151.79 | 2022-2025 | Giapreza |
| Amgen INC. | $144.22 | 2023-2025 | Tezspire |
| Mylan Specialty L.P. | $138.04 | 2019-2024 | Yupelri |
| Baxter Healthcare | $127.78 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Ani Pharmaceuticals, INC. | $109.73 | 2024-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $101.31 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Grifols USA, LLC | $98.36 | 2022-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $96.24 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $90.05 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Inspire Medical Systems, INC. | $78.45 | 2024-2025 | Inspire |
| Gilead Sciences, INC. | $72.09 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $70.12 | 2021-2025 | |
| Pfizer INC. | $69.99 | 2019-2023 | |
| Harmony Biosciences LLC | $59.84 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $50.56 | 2025 | Dupixent |
| Abbvie INC. | $44.74 | 2021-2025 | |
| Vifor Pharma, INC. | $44.31 | 2024 | Zemaira |
| Actelion Pharmaceuticals US, INC. | $40.57 | 2020-2025 | Uptravi, Opsumit |
| Idorsia Pharmaceuticals US INC | $35.36 | 2023 | Quviviq |
| Shire North American Group INC | $32.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.69 | 2022 | |
| United Therapeutics Corporation | $24.77 | 2023 | Tyvaso |
| Merck Sharp & Dohme LLC | $23.69 | 2023 | |
| Axsome Therapeutics, INC. | $23.02 | 2025 | Sunosi |
| E.R. Squibb & Sons, L.L.C. | $15.65 | 2021 | |
| Viatris Specialty LLC | $14.07 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahim Wooley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.